Profile
Daniel Deardorf is currently the Chief Executive Officer & Director at Glycologix, Inc. He previously worked as the Senior Vice President-Commercial at Flexion Therapeutics, Inc.
Daniel Deardorf active positions
| Companies | Position | Start |
|---|---|---|
Glycologix, Inc.
 Glycologix, Inc. BiotechnologyHealth Technology Glycologix, Inc. is an American biotechnology company that develops delivered biopolymers for the protection and repair of soft tissues. Glycologix was founded by Thomas Jozefiak and George Adaniya, and the CEO is Dan Deardorf. | Chief Executive Officer | 2020-12-31 |
Former positions of Daniel Deardorf
| Companies | Position | End |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
Glycologix, Inc.
Glycologix, Inc. BiotechnologyHealth Technology Glycologix, Inc. is an American biotechnology company that develops delivered biopolymers for the protection and repair of soft tissues. Glycologix was founded by Thomas Jozefiak and George Adaniya, and the CEO is Dan Deardorf. | Health Technology |
- Stock Market
- Insiders
- Daniel Deardorf
